World Library  
Flag as Inappropriate
Email this Article

Prx-07034

Article Id: WHEBN0026483314
Reproduction Date:

Title: Prx-07034  
Author: World Heritage Encyclopedia
Language: English
Subject: 5-HT6 receptor, Epix Pharmaceuticals, RS-56812, MPPF, 9-Aminomethyl-9,10-dihydroanthracene
Collection: Anilines, Chloroarenes, Organochlorides, Phenol Ethers, Piperazines
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Prx-07034

PRX-07034
Systematic (IUPAC) name
N-[1-(5-chloro-2,3-dimethoxyphenyl)ethyl]-2-methylsulfonyl-5-piperazin-1-ylaniline
Clinical data
Legal status
  • Uncontrolled
Routes Oral
Identifiers
CAS number
ATC code None
PubChem
Chemical data
Formula C21H29Cl2N3O4S 
Mol. mass 490.44 g/mol
 YesY   

PRX-07034 is a selective 5-HT6 receptor antagonist.[1] It has cognition and memory-enhancing properties and potently decreases food intake and body weight in rodents.[1][2][3][4] PRX-07034 was under development by Epix Pharmaceuticals for the treatment of obesity and cognitive impairment associated with Alzheimer's disease and schizophrenia but upon the company collapsing due to lack of funds the compound was auctioned to another corporation.[5][6][6][7]

References

  1. ^ Fone KC (November 2008). "An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function". Neuropharmacology 55 (6): 1015–22.  
  2. ^ Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE (2007). "Serotonergic drugs : effects on appetite expression and use for the treatment of obesity". Drugs 67 (1): 27–55.  
  3. ^ "PREDIX Pharmaceuticals (PRDX): Fourth Predix drug candidate enters clinical trials". 
  4. ^ a b "Epix Pharmaceuticals, Inc. Announces a Successful Auction Sale of Five Drug Program Intellectual Properties on September 30, 2009". 
  5. ^ "Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction". 

External links

  • Preclinical Data on Predix Pharmaceuticals' 5-HT6 Antagonist for Obesity and Cognitive...
  • Epix’s Experimental Drug PRX-07034 Shows Potential Benefit on Cognition, Obesity
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.